“Evaluation of Changes in Laboratory Parameters from a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Selective TYK2 Inhibitor, in Patients With Moderate-to-Severe Plaque Psoriasis”. 2024. SKIN The Journal of Cutaneous Medicine 8 (6): s442. https://doi.org/10.25251/skin.8.supp.442.